|
| 32067683 | Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. | Ann Oncol | 2020 |
| 30624595 | Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. | Ann Oncol | 2019 |
| 30857956 | Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. | Lancet Oncol | 2019 |
| 29320312 | Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. | J Clin Oncol | 2018 |
| 29856693 | Reply to J.J. Tao et al. | J Clin Oncol | 2018 |
| 29300831 | Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. | Ann Oncol | 2018 |
| 28057664 | Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. | Ann Oncol | 2017 |
| 29112701 | Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial. | Ann Oncol | 2017 |
| 25079108 | Characteristics and temporal trends in patient registries: focus on the life sciences industry, 1981-2012. | Pharmacoepidemiol Drug Saf | 2015 |
| 26428301 | NatHER: protocol for systematic evaluation of trends in survival among patients with HER2-positive advanced breast cancer. | Syst Rev | 2015 |
| 24885258 | The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. | BMC Cancer | 2014 |
| 23362014 | Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California. | Cancer | 2013 |
| 23974388 | Genetic counseling, cancer screening, breast cancer characteristics, and general health among a diverse population of BRCA genetic testers. | J Health Care Poor Underserved | 2013 |
| 23666114 | Family communication of BRCA1/2 results and family uptake of BRCA1/2 testing in a diverse population of BRCA1/2 carriers. | J Genet Couns | 2013 |
| 23544013 | Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. | PLoS Genet | 2013 |
| 23233716 | Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network. | J Clin Oncol | 2013 |
| 23247828 | Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing. | JAMA Intern Med | 2013 |
| 22144499 | Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). | Cancer Epidemiol Biomarkers Prev | 2012 |
| 29783285 | Differences in US healthcare coverage policies in BRCA testing and potential implications. | Per Med | 2012 |
| 23011509 | Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers. | Breast Cancer Res Treat | 2012 |
| 22729394 | A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. | Cancer Epidemiol Biomarkers Prev | 2012 |
| 22494806 | A Pilot study of the Sharing Risk Information Tool (ShaRIT) for Families with Hereditary Breast and Ovarian Cancer Syndrome. | Hered Cancer Clin Pract | 2012 |
| 22253144 | Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. | Hum Mutat | 2012 |
| 22274685 | Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. | JAMA | 2012 |
| 22207277 | Clinical and biomarker predictors of side effects from tamoxifen. | Breast Cancer Res Treat | 2012 |
| 22351618 | Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. | Cancer Epidemiol Biomarkers Prev | 2012 |
| 22348646 | Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. | Breast Cancer Res | 2012 |
| 21169536 | Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. | J Natl Cancer Inst | 2011 |
| 22053997 | Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. | Breast Cancer Res | 2011 |
| 22190978 | Early developments in gene-expression profiling of breast tumors: potential for increasing black-white patient disparities in breast cancer outcomes? | Per Med | 2011 |
| 21844812 | Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling. | Genet Med | 2011 |
| 21970596 | Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment. | Genome Med | 2011 |
| 21597964 | Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. | Hum Genet | 2011 |
| 21593217 | Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. | Hum Mol Genet | 2011 |
| 21385923 | The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. | Clin Cancer Res | 2011 |
| 20020220 | Update in women's health. | J Gen Intern Med | 2010 |
| 21060860 | Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. | PLoS Genet | 2010 |
| 20699375 | Communication of BRCA results and family testing in 1,103 high-risk women. | Cancer Epidemiol Biomarkers Prev | 2010 |
| 20852631 | A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. | Nat Genet | 2010 |
| 20490636 | Pre-counseling education for low literacy women at risk of Hereditary Breast and Ovarian Cancer (HBOC): patient experiences using the Cancer Risk Education Intervention Tool (CREdIT). | J Genet Couns | 2010 |
| 18855126 | Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations. | Fam Cancer | 2009 |
| 19309274 | Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. | Genet Test Mol Biomarkers | 2009 |
| 19043619 | Classifying Variants of Undetermined Significance in BRCA2 with protein likelihood ratios. | Cancer Inform | 2008 |
| 17222734 | The prognostic value of normal exercise myocardial perfusion imaging and exercise echocardiography: a meta-analysis. | J Am Coll Cardiol | 2007 |
| 17949289 | Development and pilot evaluation of novel genetic educational materials designed for an underserved patient population. | Genet Test | 2007 |
| 16418513 | Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1). | J Natl Cancer Inst | 2006 |
| 16741640 | Fecal incontinence in females older than aged 40 years: who is at risk? | Dis Colon Rectum | 2006 |
| 16882749 | Comparison of methods to measure low serum estradiol levels in postmenopausal women. | J Clin Endocrinol Metab | 2006 |
| 15625367 | Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. | J Clin Oncol | 2005 |
| 16379544 | Recruitment, genetic counseling, and BRCA testing for underserved women at a public hospital. | Genet Test | 2005 |